Tonix Pharmaceuticals HoldingTNXP -3.84%39 PS Ratio is 7.83 as of Jul. 11, 2026, which is 480% above its 10-year median of 1.35. GuruFocus rates TNXP with a GF Score™ of 39/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 930 Biotechnology companies, Tonix Pharmaceuticals Holding ranks better than 54.62% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Tonix Pharmaceuticals Holding's share price is $12.525.
Tonix Pharmaceuticals Holding's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.60. Hence, Tonix Pharmaceuticals Holding's PS Ratio for today is 7.83.
The historical rank and industry rank for Tonix Pharmaceuticals Holding's PS Ratio or its related term are showing as below:
TNXP'
s PS Ratio Range Over the Past 10 Years
Min: 0.02 Med: 1.35 Max: 14.63
Current: 7.84
During the past 13 years, Tonix Pharmaceuticals Holding's highest PS Ratio was 14.63. The lowest was 0.02. And the median was 1.35.
TNXP's PS Ratio is ranked better than 54.62% of 930
companies
in the Biotechnology industry
Industry Median: 9.515
vs TNXP: 7.84
Tonix Pharmaceuticals Holding (NAS:TNXP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Tonix Pharmaceuticals Holding PS Ratio Related Terms
Tonix Pharmaceuticals Holding PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tonix Pharmaceuticals Holding PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's PS Ratio distribution charts can be found below:
* The bar in red indicates where Tonix Pharmaceuticals Holding's PS Ratio falls into.
Tonix Pharmaceuticals Holding PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Tonix Pharmaceuticals Holding's Share Price of today is $12.525. Tonix Pharmaceuticals Holding's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.60.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Tonix Pharmaceuticals Holding (TNXP) has a PS Ratio of 7.83 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tonix Pharmaceuticals Holding and its competitors. This is 480% above median its historical median of 1.35. Over the past decade, Tonix Pharmaceuticals Holding's PS Ratio has ranged from 0.02 to 14.63. According to the industry distribution chart, Tonix Pharmaceuticals Holding ranks #422 out of 930 companies in the Biotechnology industry, placing it in the top 45.4%.
Is Tonix Pharmaceuticals Holding's PS Ratio too high?
Tonix Pharmaceuticals Holding's current PS Ratio of 7.83 is 480% above median its 10-year median of 1.35. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 14.63. The Biotechnology industry median PS Ratio is 9.52. Tonix Pharmaceuticals Holding's value of 7.83 is 17.7% below this industry median. Based on the distribution chart, Tonix Pharmaceuticals Holding ranks #422 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's PS Ratio compare to ALEC and IMUX?
According to the Biotechnology industry distribution chart, Tonix Pharmaceuticals Holding ranks #422 out of 930 companies for PS Ratio. This puts Tonix Pharmaceuticals Holding in the upper half of its industry. The industry median PS Ratio is 9.52. Tonix Pharmaceuticals Holding's value of 7.83 is 17.7% below this benchmark. Historically, Tonix Pharmaceuticals Holding's own PS Ratio has ranged from 0.02 to 14.63 over the past decade. While the company's 10-year median is 1.35 vs. the industry median of 9.52, Tonix Pharmaceuticals Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tonix Pharmaceuticals Holding's current PS Ratio of 7.83 is 17.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tonix Pharmaceuticals Holding and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tonix Pharmaceuticals Holding's current PS Ratio is 7.83, which is 480% above median its own 10-year median of 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $12.53 — trading 615.7% above its estimated fair value. The current PS Ratio is 7.83, which is 480% above median its 10-year median of 1.35 and 17.7% below the Biotechnology industry median of 9.52. Tonix Pharmaceuticals Holding's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current PS Ratio is 7.83 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued.
The current stock price of $12.53 is trading 615.7% above its estimated GF Value™ of $1.75.
GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.
Key valuation signals for TNXP:
PS Ratio: 7.83 (480% above median its 10-year median of 1.35)
GF Value™: $1.75 vs. price of $12.53 (615.7% above fair value)
Industry Position: 17.7% below the Biotechnology median (#422 of 930)
No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tonix Pharmaceuticals Holding Business Description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
39GF Score
Get the complete analysis for TNXP
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNXP has been successfully added to your 
